180
Participants
Start Date
February 24, 2021
Primary Completion Date
December 8, 2025
Study Completion Date
December 8, 2025
CC-95266
Specified dose on specified days
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
Bendamustine
Specified dose on specified days
Local Institution - 005, Birmingham
Local Institution - 011, New York
Local Institution - 008, Baltimore
Local Institution - 001, Nashville
Local Institution - 006, Dallas
Local Institution - 002, Denver
Local Institution - 012, San Francisco
Local Institution - 003, Seattle
Local Institution - 009, Duarte
Local Institution - 010, Boston
Juno Therapeutics, a Subsidiary of Celgene
INDUSTRY